Navigation Links
OncoGenex Pharmaceuticals, Inc. - Journal of Clinical Oncology Publishes Data from Randomized Phase 2 Custirsen Trial
Date:9/22/2010

on with docetaxel/prednisone, measuring the effect of custirsen on serum clusterin levels and describing time to progression and overall patient survival. Baseline characteristics were well balanced between the treatment arms.

About Custirsen

Custirsen is designed to inhibit the production of clusterin, a protein that is associated with cancer treatment resistance. In 2009, Teva Pharmaceutical Industries Ltd. and OncoGenex Pharmaceuticals, Inc. entered into a global license and collaboration agreement to develop and commercialize custirsen. The global Phase 3 clinical programs include both the ongoing SATURN Phase 3 trial assessing durable pain palliation as the primary endpoint for second-line chemotherapy in men with metastatic CRPC and the upcoming SYNERGY Phase 3 trial assessing survival as the primary endpoint in men with metastatic CRPC receiving first-line chemotherapy. A third Phase 3 trial assessing survival as the primary endpoint in first-line treatment of advanced, unresectable non-small cell lung cancer (NSCLC) is also planned as part of the global clinical program to commercialize custirsen.

More information on the SATURN trial is available on the OncoGenex website at http://oncogenex.com/clinicalTrials/index.html.

Custirsen has received Fast Track designation from the U.S. Food and Drug Administration (FDA). Both the Prostate Cancer SATURN trial and the SYNERGY trial are being conducted through the Special Protocol Assessment (SPA) process. In addition, the European Medicines Agency indicated that the Committee for Medicinal Products for Human Use was in overall agreement with the custirsen development plan for commercialization.

About OncoGenex

OncoGenex is a biopharmaceutical company committed to the development and commercialization of new cancer therapies that address treatment resistance in cancer patients. OncoGenex has a deep oncology pipeline
'/>"/>

SOURCE OncoGenex Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. OncoGenex Reports Second Quarter Financial Results
2. OncoGenex Pharmaceuticals Announces Initiation of a Phase 3 Trial in Men with Metastatic Prostate Cancer
3. OncoGenex Pharmaceuticals to Present at the 9th Annual Needham Healthcare Conference
4. OncoGenex Reports First Quarter Financial Results
5. OncoGenex Pharmaceuticals to Webcast Discussion of Financial Results for Fourth Quarter and Fiscal Year 2009
6. OncoGenex Pharmaceuticals to Present at RBC Capital Markets Healthcare Conference
7. Teva Expands Innovative Pipeline with License Agreement to Develop and Commercialize OncoGenex Late Stage Innovative Treatment for Multiple Oncology Indications
8. OncoGenex Pharmaceuticals to Host Investor Conference Call at 8:30 a.m. ET, December 21, 2009
9. OncoGenex Reports Third Quarter 2009 Financial Results
10. OncoGenex Pharmaceuticals to Release Third Quarter 2009 Financial Results
11. OncoGenex Pharmaceuticals CEO Named Canadas Pacific Ernst & Youngs Entrepreneur Of The Year(R) in the Health Sciences Category
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/30/2014)... 30, 2014  Decision Resources Group finds that ... in the United States ... penetration will be the level of savings achievable ... expected lower cost to patients. Payers plan to ... their pricing expectations in order to encourage physician ...
(Date:7/30/2014)... 2014  Replikins Ltd. today released new data on ... Before the current outbreaks, the mean Ebola Reston gene ... between 1995 and 2002 was 1.1; the mean Replikin ... sixteen-fold in 2013, thus predicting the current outbreaks in ... been shown to be able to predict outbreaks (1). ...
(Date:7/30/2014)... AZ (PRWEB) July 30, 2014 Sales ... the launch of blended sales training programs for companies ... sales training programs used by thousands of salespeople over ... blended sales training program can be customized to address ... , The blended sales training program consists ...
(Date:7/30/2014)... NY (PRWEB) July 30, 2014 July ... (Twitter: @APDN), a biotechnology firm that provides DNA-based authentication ... E. Hogan, Ph.D. Vice President of Life Sciences, a ... , Dr. Hogan will lead APDN’s drive ... business relationships with biotech and healthcare customers, provide guidance ...
Breaking Biology Technology:Surveyed U.S. Payers Expect Cost Savings to MCOs and Patients to be the Strongest Drivers of Biosimilar Uptake 2Surveyed U.S. Payers Expect Cost Savings to MCOs and Patients to be the Strongest Drivers of Biosimilar Uptake 3Sales Horizons Launches New Blended Sales Training Programs to Companies Engaged in Complex B2B Sales 2Sales Horizons Launches New Blended Sales Training Programs to Companies Engaged in Complex B2B Sales 3Dr. Michael E. Hogan, Ph.D., Joins Applied DNA Sciences as Vice President, Life Sciences 2Dr. Michael E. Hogan, Ph.D., Joins Applied DNA Sciences as Vice President, Life Sciences 3
... Ash ... the company is in the initial phases of a multi-year $6 million expansion project ... located in Riverview, Michigan. Expansions will include a new reactor bay and warehouse. ... Detroit, MI (PRWEB) ...
... Sept. 30 InteKrin Therapeutics Inc. announced today positive results ... the 45th European Association for the Study of Diabetes ... data will be presented at 1:45 PM Friday, October 2, ... His presentation is entitled "Impact of INT131 Besylate, a ...
... September 30 , - 76% ... Glycemic Control Versus Lantus(R) , Sanofi-aventis ... of a,head-to-head study providing further evidence on the efficacy of ... insulin detemir. The study was presented during the 45th,Annual Meeting ...
Cached Biology Technology:Ash Stevens Plans $6 Million Facility Expansion to Bolster CMC Capabilities 2InteKrin Therapeutics Presents Positive INT131 Phase 2b Results at the 45th Annual European Association for the Study of Diabetes Meeting 2Superior Efficacy-dose Ratio for Lantus(R) Over detemir 2Superior Efficacy-dose Ratio for Lantus(R) Over detemir 3Superior Efficacy-dose Ratio for Lantus(R) Over detemir 4Superior Efficacy-dose Ratio for Lantus(R) Over detemir 5
(Date:7/30/2014)... University,s College of Engineering recently received a $330,000 ... project, "Nanoparticle-directed synthesis of organic nanorods." , ... the creation and utilization of functional materials, devices, ... major bottleneck in scaling up nanotechnology is the ... materials into one device. A research team led ...
(Date:7/30/2014)... injury (SCI), traumatic brain injury (TBI) and peripheral nerve ... learned over the past 30 years regarding both the ... growth, but this large body of information has not ... his team from University of Miami in USA proposed ... consensus is emerging that one contributing factor is a ...
(Date:7/30/2014)... Washington, DCToday scientists unveiled the first high-resolution map ... the entire country of Per. The new and ... a sea change for future market-based carbon economies. ... extremely high ecological diversity and it provides the ... degradation for conservation, land use, and enforcement purposes. ...
Breaking Biology News(10 mins):NSF grant to Wayne State supports new concept for manufacturing nanoscale devices 2Peru's carbon quantified: Economic and conservation boon 2Peru's carbon quantified: Economic and conservation boon 3
... to promote interdisciplinary research that addresses complex interactions ... in recent years, but success is often elusive. ... social scientists attempting such work, Eric D. Roy ... a variety of institutions surveyed researchers at all ...
... MADISON, Wis. By any measure, tuberculosis (TB) is a wildly ... every corner of the world, with a new infection of a ... a new analysis of dozens of tuberculosis genomes gathered from around ... TB is so prevalent and how it evolves to resist countermeasures. ...
... August 2013 Metals such as iron, copper, and ... years, studies have shown that these nutritionally-essential metals are ... animal models of AD. Scientists are now exploring whether ... or are indicative of other ongoing pathologic processes. ...
Cached Biology News:Survey highlights barriers to interdisciplinary environmental science 2Tuberculosis genomes portray secrets of pathogen's success 2Elevated levels of copper in amyloid plaques associated with neurodegeneration in mouse models of AD 2
... (1995) This volume provides excellent ... for the study of major HIV proteins ... ribonuclease H, integrase and protease. Expression of ... Tat and Rev assays; HIV/CD4 interactions; transient ...
Monkey IL-2 ELISPOT Kit with white/opague microtiter plates...
Tachykinin (H-2)...
Human GATA-2 Affinity Purified Polyclonal Ab...
Biology Products: